Mild to moderate persistent asthma

Active Ingredient: Montelukast

Indication for Montelukast

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Montelukast is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting ฮฒ-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom montelukast is indicated in asthma, Montelukast 10 mg film-coated tablets can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

For this indication, competent medicine agencies globally authorize below treatments:

4-5 mg once daily

Route of admnistration

Oral

Defined daily dose

4 - 5 mg

Dosage regimen

From 4 To 5 mg once every day

Detailed description

5 mg for paediatric patients 6 to 14 years of age.

4 mg for paediatric patients 2 to 5 years of age.

General recommendations

The therapeutic effect of Montelukast on parameters of asthma control occurs within one day. Montelukast may be taken with or without food. Patients should be advised to continue taking Montelukast even if their asthma is under control, as well as during periods of worsening asthma. Montelukast should not be used concomitantly with other products containing the same active ingredient, montelukast.

Therapy with montelukast in relation to other treatments for asthma

Montelukast can be added to a patient’s existing treatment regimen.

Inhaled corticosteroids

Treatment with can be used as add-on therapy in patients when inhaled
corticosteroids plus “as needed” short acting ฮฒ-agonists provide inadequate clinical control. Montelukast should not be abruptly substituted for inhaled corticosteroids.

Dosage considerations

Should be taken in the evening.

Active ingredient

Montelukast

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. ฮคhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.

Read more about Montelukast

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.